Proteomic shifts post plasma cell therapy in AL amyloid plaques and potential implications for light chain directed anti-fibril monoclonal antibodies

Authors

Angela A. Dispenzieri (ORCID: https://orcid.org/0000-0001-8780-9512)
Morie A. Gertz (ORCID: https://orcid.org/0000-0002-3853-5196)
Ellen D. McPhail (ORCID: https://orcid.org/0000-0001-6918-3376)
Matthew J. Rees (ORCID: https://orcid.org/0000-0001-8360-2952)
Surendra Dasari (ORCID: https://orcid.org/0000-0002-7972-3556)
M. Cristine Charlesworth (ORCID: https://orcid.org/0000-0001-7481-817X)
Taxiarchis Kourelis (ORCID: https://orcid.org/0000-0001-8573-9434)
Eli Muchtar (ORCID: https://orcid.org/0000-0003-2210-2174)
Navin R. Gupta (ORCID: https://orcid.org/0000-0001-6445-3496)
Shaji Kumar
Christopher J. Dick
Emilie Anderson
Samantha N Quang

Institutions

Mayo Clinic in Arizona (US)
Mayo Clinic in Florida (US)

Publication Details

Journal: Haematologica
Published: 2025-07-24
DOI: https://doi.org/10.3324/haematol.2025.288217
Primary Topic: Amyloidosis: Diagnosis, Treatment, Outcomes
Type: article
Field-Weighted Citation Impact: 0.00

Funders

Pfizer
AstraZeneca
Sanofi
Alexion Pharmaceuticals
Alnylam Pharmaceuticals
Celgene

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Proteomic shifts post plasma cell therapy in AL amyloid plaques and potential implications for light chain directed anti-fibril monoclonal antibodies

Angela A. Dispenzieri, Morie A. Gertz, Ellen D. McPhail, Matthew J. Rees et al.

Jul 24, 2025

Haematologica

Amyloidosis: Diagnosis, Treatment, Outcomes

article

Proteomic shifts post plasma cell therapy in AL amyloid plaques and potential implications for light chain directed anti-fibril monoclonal antibodies

Angela A. Dispenzieri, Morie A. Gertz, Ellen D. McPhail, Matthew J. Rees, Surendra Dasari, M. Cristine Charlesworth, Taxiarchis Kourelis, Eli Muchtar, Navin R. Gupta, Shaji Kumar, Christopher J. Dick, Emilie Anderson, Samantha N Quang

July 24, 2025article en

Abstract

No abstract available for this paper.

HaematologicaVol. 111(1)

Mayo Clinic in Arizona (US), Mayo Clinic in Florida (US)

Pfizer, AstraZeneca, Sanofi, Alexion Pharmaceuticals, Alnylam Pharmaceuticals, Celgene

Openalex Percentile: Top 84%

Amyloidosis: Diagnosis, Treatment, Outcomes

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Proteomic shifts post plasma cell therapy in AL amyloid plaques and potential implications for light chain directed anti-fibril monoclonal antibodies — Angela A. Dispenzieri, Morie A. Gertz, et al. · Haematologica (2025) | TGRS Research Map | TGRS